Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera
about
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinibThe Role of Reactive Oxygen Species in Myelofibrosis and Related NeoplasmsNew Therapeutic Approaches in Polycythemia VeraPolycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and managementMonitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging ApproachesRuxolitinib in the treatment of polycythemia vera: patient selection and special considerationsRefractory anemia with ring sideroblasts and RARS with thrombocytosisManagement of polycythaemia vera: a critical review of current data.Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinibEmerging drugs for myelofibrosis.A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea.Ruxolitinib versus standard therapy for the treatment of polycythemia vera.2016 WHO Clinical Molecular and Pathological Criteria for Classification and Staging of Myeloproliferative Neoplasms (MPN) Caused by MPN Driver Mutations in the JAK2, MPL and CALR Genes in the Context of New 2016 WHO Classification: Prognostic and TExperience with ruxolitinib in the treatment of polycythaemia vera.Polycythemia Vera Management and Challenges in the Community Health Setting.HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humansAnnual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.Pharmacological management of essential thrombocythemia.Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.Investigational Janus kinase inhibitors.The Ph-positive and Ph-negative myeloproliferative neoplasms: some topical pre-clinical and clinical issues.How I treat essential thrombocythemia.Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Rα.Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.Current and future treatment options for polycythemia vera.Emerging treatments for essential thrombocythemiaMechanisms of thrombogenesis in polycythemia veraThe orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera.Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b.Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patientsAllogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemiaSprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responsesJAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.Update on JAK2 Inhibitors in Myeloproliferative NeoplasmDepletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera
P2860
Q26750696-0A1985CC-C7C0-44B7-9AB4-97FEACC3A9C9Q26779929-A0DCCDD4-61FF-4E06-8C3E-8DA04F647B28Q26795677-79127C9F-38BE-4BE9-977B-9ED14EC16D04Q26851894-78615D48-5937-423C-A96F-E2ED0A86018FQ28076096-01E87DFD-1B29-4A05-82D8-6A5381942DEBQ28078404-F6BEBF8E-949F-40A4-AA0C-98029C710289Q28083238-E71487FF-75BF-4FF5-BF02-E2A01168327BQ31009757-4E6AD7E3-F1FD-4461-A150-E9A375910C87Q33398180-E09FC65E-8476-40F8-94FE-F7C8A84F6B5EQ33402522-11EE1246-F1E8-4288-A656-559435BB4BB3Q33404574-AB8493A2-4B40-4AD0-AA8B-8197DC6A7142Q33411637-4E6171BB-3B22-49C1-A060-CC407BB1070DQ33420037-DE92B258-B81F-434D-93BB-3F6E4210D18BQ33572605-8A928E12-57FD-4CA8-BE97-FDE01491D224Q33605624-4727E9FF-9CF9-4C52-A2DA-D4A47ACF6936Q33803036-5C08EB47-3837-43CD-9FA8-5D3CED6411EDQ34162151-33BEA6A7-9C47-4AD9-A00C-8979B8D629ADQ34166859-0062F796-FEB3-4161-B4EF-AFFA82C8D15CQ34302770-5F47C1BF-B628-4F4D-9C98-63C66D405067Q34344384-B527E1D1-661F-4348-B621-C9DB753CD6E3Q34370771-3629ADA4-D835-472B-80D5-5042219F5855Q34648724-AF024A11-00B5-449C-9939-C658354F9A81Q34750582-A6A23465-DF26-452F-8CF3-12518ED05684Q35132271-28FBB14C-010D-483B-834F-4B98907A3488Q35203067-C333DD43-32C6-43E1-BAE9-F82C565E9F32Q35433259-49CCFFB8-AE5B-46A0-BE76-DA87BE404412Q35572748-F3C60857-1FAB-4CE0-A63C-16849D77F73BQ35683853-069E0BED-324F-450E-B52C-308959CFA39FQ35738656-3FD0DAFC-E7C3-4D7A-BD03-EEC641930BBCQ35743852-5E233CBB-00E6-4135-A014-540BE773CE34Q35944657-ECDE8867-66DF-4B33-AA54-8BADD9F13B90Q36169641-04F7E045-1872-485E-9BE6-FC08904FB611Q36169783-ECDD037E-A8BF-4858-A23D-2DF260173E08Q36311347-2B73F35C-9374-4790-88CD-3E08EC7B224BQ36366962-2915219A-156D-4A55-8352-07961B5C71F7Q36404698-C5E74353-D2B3-4A87-80A3-55056F0BAB13Q36452049-6661C8EA-9861-429E-9103-0840A829F0CAQ36612537-FB29F841-DD29-4B84-9434-327131B9E21BQ36612569-2A6F8C0D-4333-45B0-8017-FB49BAC605B4Q36814639-B34BC3BC-DCA6-454B-BBDF-F79598470E5A
P2860
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Pegylated interferon alfa-2a y ...... cythemia and polycythemia vera
@en
type
label
Pegylated interferon alfa-2a y ...... cythemia and polycythemia vera
@en
prefLabel
Pegylated interferon alfa-2a y ...... cythemia and polycythemia vera
@en
P2093
P2860
P50
P356
P1476
Pegylated interferon alfa-2a y ...... cythemia and polycythemia vera
@en
P2093
Alfonso Quintás-Cardama
Mary Ann Richie
Rajyalakshmi Luthra
Taghi Manshouri
P2860
P304
P356
10.1200/JCO.2009.23.6075
P407
P50
P577
2009-10-13T00:00:00Z